![Top 5 things to watch in markets in the week ahead](https://i-invdn-com.investing.com/news/moved_small-LYNXNPEK340EF_L.jpg)
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RKV | CBOE Canada | CAD | Real-time | |
RKV | TSXV | CAD | Delayed |
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
Name | Age | Since | Title |
---|---|---|---|
Neil Sankar | - | 2021 | Member of Scientific Advisory Board |
Artem Cherkasov | - | 2023 | Senior AI, Medicinal Chemistry Advisor & Member of Scientific Advisory Board |
Wang Shen | - | 2021 | Member of Scientific Advisory Board |
Alfredo Javier De Lucrezia | 56 | 2019 | Independent Director |
Jeffrey A. Bacha | 56 | 2021 | Executive Chairman |
Michael Liggett | 64 | 2021 | Independent Director |
Petra Hamerlik | - | 2023 | Member of Scientific Advisory Board |
Dennis M. Brown | 74 | 2021 | Chairman of Scientific Advisory Board & Independent Director |
Leonard E. Post | 71 | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review